Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Other financing activities: 2012-2025

Historic Other financing activities for Anika Therapeutics (ANIK) over the last 10 years, with Sep 2025 value amounting to $13,000.

  • Anika Therapeutics' Other financing activities fell 38.10% to $13,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year decrease of 34.83%. This contributed to the annual value of $2.6 million for FY2024, which is 20.77% up from last year.
  • As of Q3 2025, Anika Therapeutics' Other financing activities stood at $13,000, which was down 84.34% from $83,000 recorded in Q2 2025.
  • Anika Therapeutics' Other financing activities' 5-year high stood at $2.3 million during Q1 2024, with a 5-year trough of -$218,000 in Q4 2021.
  • In the last 3 years, Anika Therapeutics' Other financing activities had a median value of $107,000 in 2023 and averaged $574,000.
  • Over the last 5 years, Anika Therapeutics' Other financing activities had its largest YoY gain of 1,628.00% in 2023, and its largest YoY loss of 700.00% in 2023.
  • Over the past 5 years, Anika Therapeutics' Other financing activities (Quarterly) stood at -$218,000 in 2021, then soared by 99.54% to -$1,000 in 2022, then slumped by 700.00% to -$8,000 in 2023, then skyrocketed by 1,050.00% to $76,000 in 2024, then tumbled by 38.10% to $13,000 in 2025.
  • Its Other financing activities was $13,000 in Q3 2025, compared to $83,000 in Q2 2025 and $1.5 million in Q1 2025.